8-K: STRATA Skin Sciences Reports Q4 and Full-Year 2024 Financial Results, Highlights Turnaround Progress

STRATA Skin Sciences announces improved Q4 2024 financial results with revenue up 10% and progress in its turnaround strategy focused on cost efficiency and revenue per device.

Summary

• STRATA Skin Sciences reported its fourth quarter and full-year 2024 financial results on March 27, 2025.
• Q4 revenue increased by 10% to $9.6 million compared to $8.7 million in the prior year.
• Global net recurring XTRAC revenue was $5.5 million in Q4, with international growth offsetting a slight domestic decline.
• Average net revenue per domestic XTRAC system rose to $5,906, a 6% year-over-year increase, on 864 systems.
• Total recurring revenue increased by 3% to $5.8 million in Q4, driven by international growth and TheraClear contributions.
• Equipment revenue increased by 23% to $3.8 million, marking the highest level in two years.
• Full-year 2024 revenue was $33.6 million, a slight increase from $33.4 million in 2023.
• Equipment segment growth of 5% offset a 2% decline in the recurring segment for the full year.
• Gross margin improved to 60.1% in Q4 2024, up 480 basis points from 55.3% in Q4 2023.
• Operating expenses declined by 8.5% to $22.7 million in 2024, adjusting for a one-time accrued expense and non-cash impairment.
• The company implemented a turnaround focusing on cost efficiency and improving revenue per device.
• Capex spend was reduced by 67% year-over-year for full-year 2025 by removing and refurbishing underutilized machines.
• A registered direct offering closed on July 23, 2024, raising $2.1 million in gross proceeds.
• The XTRAC Momentum 1.0 device received approval in Japan, driving international recurring revenue growth.
• A complaint was filed against LaserOptek for unfair competition, resulting in a court order against deceptive advertising.
• Net loss for the fourth quarter of 2024 was $4.5 million, or EPS of negative $1.18 per basic and diluted common share.
• Net loss for the full year 2024 was $10.1 million, including the $1.8 million accrual and the $3.9 million impairment expense, resulting in a net loss of $2.65 per basic and diluted common share.
• Cash, cash equivalents, and restricted cash at December 31, 2024 were $8.6 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company reported a net loss, there are clear signs of improvement in revenue growth, gross margin, and operational efficiency. The successful capital raise and international expansion are also positive indicators.

Positives

• Revenue increased by 10% in Q4 2024 compared to the previous year.
• Gross margin improved significantly in Q4 2024.
• Operating expenses decreased in 2024.
• The company successfully reduced capex spend.
• International sales showed strong growth.
• The company successfully defended itself against unfair competition from LaserOptek.
• Non-GAAP adjusted EBITDA improved year-over-year.

Negatives

• The company reported a net loss for both the fourth quarter and the full year 2024.
• Full year revenue only increased slightly compared to the previous year.
• Global recurring revenue for the full year 2024 decreased slightly compared to the full year 2023.
• Impairment expense for the full year 2024 was higher than the full year 2023.

Risks

• The company faces risks related to financial, economic, business, competitive, market, and regulatory factors.
• Adverse market conditions, labor supply shortages, or supply chain interruptions could impact the company.
• International conflicts and political factors could pose risks.
• The company's ability to launch and sell new products is subject to uncertainty.
• The company's ability to develop successful marketing campaigns is not guaranteed.

Future Outlook

The company is focused on continuing its turnaround strategy, improving revenue per device, and driving cost efficiencies.

Management Comments

• STRATA's President and CEO, Dr. Dolev Rafaeli, stated that the fourth quarter results highlight the success in implementing the strategy to shift the existing installed base to more productive centers.
• Dr. Rafaeli noted the increase in average revenue per device and the improvement in operating margins.
• Dr. Rafaeli also highlighted the significant traction in international markets, particularly in the Equipment segment.

Industry Context

STRATA Skin Sciences operates in the medical technology industry, specifically focusing on dermatology and aesthetics. The company competes with other medical device manufacturers and providers of dermatological treatments. The legal action against LaserOptek highlights the competitive landscape and the importance of protecting intellectual property and fair marketing practices.

Comparison to Industry Standards

• It's difficult to provide a precise comparison to industry standards without specific competitor data, but generally, a gross margin of 60.1% is considered healthy in the medical device industry.
• Companies like Cynosure, Cutera, and Candela are key competitors in the aesthetic laser market.
• Comparing STRATA's revenue growth and profitability to these companies would provide a better understanding of its relative performance.
• The improvement in adjusted EBITDA suggests positive progress in operational efficiency, which is a key metric for investors in the medical device sector.

Legal Proceedings

• STRATA filed a complaint against LaserOptek for unfair competition, resulting in a court order against deceptive advertising.
• On February 28, 2025, Strata filed a motion for civil contempt against LaserOptek for violating that court order.

Stakeholder Impact

• Shareholders may be encouraged by the improved financial performance and turnaround progress.
• Employees may benefit from the company's focus on efficiency and growth.
• Customers may experience improved service and support as the company optimizes its operations.

Next Steps

• STRATA management will host a conference call on March 27, 2025, to review financial results and provide a corporate update.
• The company will continue to focus on its turnaround strategy, improving revenue per device, and driving cost efficiencies.
• The company will continue to pursue legal action against LaserOptek to protect its intellectual property and ensure fair competition.

Key Dates

Keywords

STRATA Skin Sciences, financial results, XTRAC, revenue, dermatology, medical technology, TheraClear, EBITDA